wr 99210 has been researched along with isoniazid in 1 studies
| Studies (wr 99210) | Trials (wr 99210) | Recent Studies (post-2010) (wr 99210) | Studies (isoniazid) | Trials (isoniazid) | Recent Studies (post-2010) (isoniazid) |
|---|---|---|---|---|---|
| 59 | 0 | 12 | 21,815 | 960 | 4,493 |
| Protein | Taxonomy | wr 99210 (IC50) | isoniazid (IC50) |
|---|---|---|---|
| Myeloperoxidase | Homo sapiens (human) | 4.85 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | Mycobacterium tuberculosis H37Rv | 8.29 | |
| Putative FAD-containing monooxygenase MymA | Mycobacterium tuberculosis H37Rv | 4.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gerum, AB; Jacobus, DP; Jensen, NP; Sherman, DR; Sibley, CH; Ulmer, JE | 1 |
1 other study(ies) available for wr 99210 and isoniazid
| Article | Year |
|---|---|
Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Folic Acid Antagonists; Genetic Complementation Test; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Rifampin; Saccharomyces cerevisiae; Tetrahydrofolate Dehydrogenase; Triazines | 2002 |